The research team, led by clinicians and computational scientists at the University Hospital Würzburg together with collaborators at Charité – Universitätsmedizin Berlin, followed 100 people with Parkinson’s disease who underwent subthalamic deep brain stimulation between 2010 and 2020. The patients, whose average age at surgery was just over 60 years, underwent detailed assessments before the operation, again one year afterward, and in a subset of 33 patients, at three to five years after surgery. Rather than examining each symptom in isolation, the investigators deployed a battery of statistical tools, including unsupervised clustering, principal component analysis, and moderation models, to capture the joint structure of motor, cognitive, and mood symptoms as they evolved over time. The goal was to see whether deep brain stimulation preserves or reshapes the hidden architecture of the disease, and whether non-motor burden could explain why some patients regain mobility while others do not.

The technical pipeline was deliberately conservative. Missing clinical values were imputed using chained equations fitted only on pre-operative data, so that follow-up information could not leak backward and bias the baseline picture. Principal component analysis was fitted exclusively on the pre-surgery scores, and every follow-up visit was then projected into that fixed baseline space, allowing the researchers to track each patient’s trajectory along stable clinical dimensions rather than comparing shifting mathematical axes. Cluster stability was verified with 500 bootstrap resamples, and the robustness of the two-cluster solution was confirmed across 20 multiply-imputed datasets, with a mean adjusted Rand index of 0.945 against the primary solution. P values were corrected for false discovery across all simultaneous comparisons, and heteroscedasticity-consistent standard errors guarded the moderation models against uneven variance.

The first striking result concerned how patients group together before surgery. Unsupervised clustering of 22 clinical sub-domain scores revealed two reproducible profiles, a higher-impairment and a lower-impairment group, separated primarily by axial motor features: postural instability, gait, posture, and mobility, with smaller but meaningful differences in anxiety and depressive symptoms. The separation between clusters was large by conventional standards, with Cohen’s d values approaching or exceeding 1.9 for postural instability and gait. When the researchers projected the one-year post-operative assessments into this baseline cluster space, 84 percent of the patients who had started in the higher-impairment profile moved into the lower-impairment profile, while 95 percent of those who began in the lower-impairment group stayed there. Because the two profiles sit along a continuous severity dimension rather than representing truly distinct disease subtypes, the authors interpret this migration as improvement along a single axis of clinical burden, a continuous slide toward wellness that mirrors the well-documented efficacy of the stimulation itself.

The second major finding is perhaps the most sobering. Across every timepoint, the single largest source of between-patient clinical variance was a core motor triad: gait, mobility, and freezing of gait. This component explained 35 percent of the variance before surgery, 32 percent at one year, and still 28 percent at three to five years, and it was the only component to survive a rigorous permutation null, meaning that the other axes of variation were largely domain-specific and statistically fragile. In plain terms, even after electrodes have silenced tremor and rigidity, the way a patient walks remains the dominant thing that separates one person with Parkinson’s from another. This aligns with a growing body of evidence that axial symptoms, which depend on brainstem and cholinergic circuits as much as on the dopaminergic pathways that stimulation modulates, respond poorly to subthalamic stimulation and remain the leading source of unmet expectations after surgery.

The longitudinal projections added a temporal dimension to this picture. The motor severity axis dropped significantly in the first year after surgery, consistent with genuine motor improvement, but by three to five years it had drifted back toward baseline, echoing earlier reports of initial gait gains of more than 40 percent followed by substantial long-term decline. Meanwhile, a memory-dominated component, which captured 17 percent of between-patient variance at baseline, rose to 24 percent by the long-term follow-up, and within-patient projected memory scores increased significantly over the same interval. Mood features showed no significant change at one year but a small, statistically significant worsening at three to five years. The researchers are careful to note that these shifts reflect changes in relative heterogeneity and domain-specific burden rather than a wholesale reorganization of the disease, and that the covariance structure itself, tested with Procrustes analysis against 5,000 permutations, remained significantly aligned across timepoints.

The third and most clinically provocative finding emerged from the moderation analysis. Using analysis of covariance models that regressed each one-year motor outcome on its baseline value, a non-motor moderator, and their interaction, while adjusting for age and disease duration, the team asked whether pre-operative mood and cognition shaped the degree of motor recovery. The answer, in exploratory analyses, was yes. Higher baseline non-motor burden predicted poorer recovery of the composite gait-and-mobility triad, with an interaction coefficient of 1.45. Decomposed into individual features, the strongest culprits were psychomotor depressive symptoms, with a coefficient of 2.16, psychosomatic depressive symptoms, and language function, each associated with smaller mobility gains. Worse baseline orientation, by contrast, was associated with greater improvement. At the one-year follow-up, anxiety measured at the same visit showed a concurrent association with both the composite motor score and mobility, with coefficients of 2.30 and 2.81 respectively. Gait and freezing of gait themselves showed no significant moderators after correction, suggesting that the mood effect is concentrated in mobility rather than in freezing episodes.

Why would depression and anxiety written into a patient’s chart before surgery echo through their walking a year after electrodes are implanted? The authors point to the anatomy of the subthalamic nucleus itself, which is not a purely motor relay but a hub of striato-thalamo-cortical circuits serving cognitive and limbic functions as well. Gait and postural control demand constant cognitive-motor integration, the very faculty that frontal-executive dysfunction erodes, and symptom-specific tractography work has shown that axial motor symptoms are mediated by distinct white matter pathways connecting the subthalamic nucleus to the supplementary motor cortex and brainstem, rather than by the primary motor circuits that standard stimulation parameters most effectively engage. Shared prefrontal-subthalamic circuitry involved in both affective regulation and motor control offers a plausible substrate for the observed interactions, and some researchers have even proposed that patients implicitly trade cognitive performance for gait stability, a bargain that stimulation does not resolve.

The authors are appropriately cautious about how far these conclusions can be pushed. The study was retrospective, and strict inclusion criteria trimmed 180 consecutive patients down to 100, potentially selecting for more completely assessed cases. The long-term follow-up sample of 33 patients is modest, though comparable to other studies at equivalent timepoints, and that subset was enriched for higher baseline motor severity, which may have tempered the apparent long-term motor findings. The moderation analyses are explicitly exploratory, and no external cohort with harmonized multi-domain longitudinal data was available for validation, a scarcity the authors describe as a broader problem for the field. Medication changes were addressed through sensitivity analyses: levodopa equivalent daily dose fell by a median of 56.7 percent after surgery, but residualizing this change from every post-operative score left the component structure essentially untouched, with a Procrustes distance of just 0.004 between the original and adjusted solutions.

Even with those caveats, the clinical implications are hard to ignore. If pre-operative mood burden genuinely forecasts the size of a patient’s mobility recovery, then a psychiatric evaluation belongs in every deep brain stimulation candidacy discussion, not as a gatekeeping exercise but as a prognostic tool that helps patients and clinicians set realistic expectations. And if anxiety and psychosomatic symptoms at follow-up track concurrent motor burden, then post-operative mood monitoring, and interventions that combine motor rehabilitation with psychological support, such as dual-task training, become candidate levers for protecting the very gains that surgery was meant to deliver. The authors frame these as testable hypotheses for prospective multicenter trials rather than established determinants of outcome, but the direction of travel is clear: the future of deep brain stimulation may depend less on where the electrodes land than on how completely clinicians learn to read, and treat, the whole patient before and after the current flows.

Subject of Research: The relationship between non-motor symptom burden and motor recovery after subthalamic nucleus deep brain stimulation in Parkinson's disease

Article Title: Non-motor symptoms burden and motor recovery following STN–DBS in Parkinson's disease: a data-driven longitudinal analysis

Article References: Abbas, G., Peach, R., Temuulen, U., Tang, Y., Sil, T., Kufner, A., Endres, M., Volkmann, J., Lange, F., & Reich, M. (2026). Non-motor symptoms burden and motor recovery following STN–DBS in Parkinson's disease: a data-driven longitudinal analysis. Journal of Neurology, 273(10), Article 636. https://doi.org/10.1007/s00415-026-14160-x

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14160-x

Keywords: Parkinson's disease, deep brain stimulation, subthalamic nucleus, non-motor symptoms, gait, freezing of gait, mobility, depression, anxiety, principal component analysis, longitudinal study, neurology

The new analysis, published in Nature Mental Health by a team at Sunnybrook Health Sciences Centre and the University of Toronto, pooled data from 25 clinical trials of DBS for treatment-resistant depression, encompassing both open-label studies and randomized controlled trials. Led by neurosurgeon Benjamin Davidson and psychiatrist Peter Giacobbe, the researchers applied a random-effects meta-analytic framework, the statistical gold standard for combining results across heterogeneous studies, to quantify how much depressive symptoms changed after stimulation began. Their conclusion is striking in its consistency: symptom improvement was evident across every time window examined, and the effect sizes, a standardized measure of how large a treatment response is, were not merely statistically significant but clinically enormous.

The numbers deserve close attention. At short-term follow-up, spanning six to nine months after DBS initiation, the pooled standardized mean change was 2.77. At moderate-term follow-up of twelve to twenty-four months, it rose to 3.15. And beyond the two-year mark, the effect size climbed to 3.87. To put those figures in context, effect sizes above 0.8 are conventionally considered large in clinical research; values approaching 3 or 4 are extraordinarily rare in psychiatry, where even the best pharmacological and psychotherapeutic interventions for depression typically produce standardized effects well below 1.0. In plain terms, the average patient in these trials experienced a transformation in depressive symptoms that conventional treatments for this population have rarely achieved.

Perhaps the most provocative finding is the trajectory itself. Unlike most psychiatric treatments, whose benefits plateau or erode over time, DBS for treatment-resistant depression showed a dose-like relationship with duration: the longer the stimulation continued, the greater the improvement. The researchers also uncovered a subtler signal buried in the trial data. Studies that checked in on patients more frequently reported faster rates of symptom improvement, a correlation that raises intriguing questions about whether regular clinical contact, careful parameter adjustment, or simply closer therapeutic attention amplifies the device’s effects. This follow-up frequency finding echoes earlier observations in placebo-controlled antidepressant trials, where assessment schedules shaped measured outcomes, but here it points toward an actionable clinical lesson: intensive post-surgical care may be part of the treatment, not just a measurement artifact.

The team also tackled one of the field’s most contested questions: where, exactly, should the electrodes go? Over two decades, investigators have implanted stimulators in a roster of candidate targets, including the subcallosal cingulate cortex, a region of the medial prefrontal cortex implicated in rumination and negative mood; the nucleus accumbens, a hub of the reward circuitry; the ventral capsule and ventral striatum; the medial forebrain bundle, a major highway connecting mood-regulating circuits; and the bed nucleus of the stria terminalis. The meta-analysis found that neither study design nor stimulation target significantly influenced overall outcomes, suggesting that multiple nodes within overlapping depression networks can be effectively modulated. Yet a pattern emerged beneath that statistical equivalence: subcallosal cingulate stimulation produced the largest effect sizes at every time point examined, reinforcing its status as the most extensively validated target and the one anchored in the deepest mechanistic literature.

That mechanistic story began in 2005, when neurologist Helen Mayberg and colleagues published the seminal proof-of-concept study showing that chronic stimulation of the subcallosal cingulate, also called area 25, could relieve profound depression in patients who had exhausted all other options. The rationale was elegant: area 25 sits at a crossroads of the limbic system, acting as a kind of volume control for negative emotional signals that, in severe depression, become stuck in a state of pathological overdrive. Subsequent work refined the approach using connectomics, the mapping of individual patients’ white-matter tracts, to place electrodes so that stimulation current would engage a specific bundle of fibers converging on the cingulate. Studies published in 2023 and 2025 have since shown that cingulate neural dynamics can track recovery in real time, offering a biological signature of healing that clinicians can potentially read and respond to.

The field’s history, however, is not one of unbroken triumph. Two large randomized sham-controlled trials, one targeting the subcallosal cingulate and another the ventral capsule and ventral striatum, famously failed to separate active stimulation from sham surgery at their primary endpoints, dealing the field a bruising setback and leaving many psychiatrists skeptical. The new meta-analysis speaks directly to that controversy. Because it found no significant influence of study design on outcomes, the authors argue that the apparent failures of blinded trials may reflect methodological challenges, including the slow, cumulative nature of DBS response, small samples, and the difficulty of designing a convincing sham condition for an invasive procedure, rather than a true absence of efficacy. The finding that benefits continue accruing for years suggests that short blinded phases may simply be too brief to capture the treatment’s real effect.

Safety, inevitably, is part of the equation. DBS requires stereotactic neurosurgery, with its attendant risks of bleeding and infection, and chronic stimulation can produce side effects ranging from transient mood shifts to sleep disturbance and hardware complications. The meta-analysis pooled adverse event data across trials, and prior scoping reviews and a 2025 pooled analysis of 172 implanted patients have generally characterized the long-term safety profile as acceptable for a population facing otherwise intractable illness. The regulatory landscape is shifting as well: the United States Food and Drug Administration has granted a humanitarian device exemption pathway relevant to DBS for severe treatment-resistant depression, a signal that regulators are beginning to carve out a formal place for the technology in clinical practice.

The Toronto team has also made its work unusually transparent. The complete dataset underlying the meta-analysis is publicly available through Mendeley, and the analysis code is posted on the Open Science Framework, allowing independent researchers to interrogate every statistical decision. That openness matters in a field that has been burned before by overpromising, and it sets the stage for the next critical step: properly powered, blinded trials with follow-up periods long enough to match the treatment’s own timeline. The authors are explicit that their findings support sustained antidepressant effects but also provide a roadmap for establishing efficacy against placebo more rigorously and for optimizing how the therapy is delivered.

For patients trapped in the grinding darkness of treatment-resistant depression, the message from this synthesis is cautiously electrifying. A therapy once dismissed after high-profile trial failures now has pooled evidence showing effects that deepen year after year, targets whose differences are becoming understood rather than disputed, and a mechanistic framework grounded in the brain’s mood circuitry rather than trial and error. Deep brain stimulation is not a cure, and it will never be a first-line option; the surgery, the cost and the lifelong device management see to that. But for the population that has nothing left to try, the accumulating evidence suggests that a small electrical whisper delivered to the right circuits, sustained over years and accompanied by attentive clinical care, may be enough to turn the volume down on depression at last.

Subject of Research: Efficacy and safety of deep brain stimulation for treatment-resistant major depressive disorder

Article Title: Deep brain stimulation for major depressive disorder: a systematic review and meta-analysis

Article References: Manocchio, F., Profant, M. R., Abbasian, A., Enepekides, J., Rabin, J. S., Goubran, M., Meng, Y., Cao, X., Nestor, S., Hamani, C., Lipsman, N., Giacobbe, P., & Davidson, B. (2026). Deep brain stimulation for major depressive disorder: a systematic review and meta-analysis. Nature Mental Health. https://doi.org/10.1038/s44220-026-00725-2

Image Credits: AI Generated

DOI: 10.1038/s44220-026-00725-2

Keywords: deep brain stimulation, treatment-resistant depression, major depressive disorder, meta-analysis, subcallosal cingulate, neuromodulation, psychiatry, neurosurgery, nucleus accumbens, medial forebrain bundle, Nature Mental Health, brain circuits

Researchers set out to map the structural connectomes, the comprehensive wiring diagrams of neural fiber tracts, of patients with severe, treatment-refractory obsessive-compulsive disorder, and to compare how the conventional deep brain stimulation targets are embedded within each individual’s connectome. Using diffusion magnetic resonance imaging, the team reconstructed the white matter pathways that connect distant brain regions and analyzed how the stimulation sites commonly used in clinical practice relate to the broader network organization of each patient’s brain. The central question was deceptively simple: when two patients receive stimulation at the same anatomical coordinate, are they actually stimulating the same circuit?

The answer, according to the findings, is a resounding no. The study revealed substantial patient-specific differences in the structural connectivity profile of the target regions most frequently used for obsessive-compulsive disorder, including the anterior limb of the internal capsule, the ventral capsule and striatum, the nucleus accumbens, and the bed nucleus of the stria terminalis. While these targets occupy broadly similar positions across patients, the specific fiber bundles passing through and around them, and the cortical and subcortical regions they link, vary considerably from one individual to the next. A coordinate that engages a particular fronto-striatal loop in one patient may recruit a partially different set of tracts and connection patterns in another.

This variability has profound implications for a field that has traditionally relied on group-averaged atlases to guide electrode placement. Standard neurosurgical practice often positions electrodes according to population-level templates, on the assumption that a given target occupies a comparable network position in most patients. The new connectomic analysis challenges that assumption directly. If the structural context of a target differs substantially across patients, then identical electrode placements may produce heterogeneous network effects, potentially explaining some of the striking inconsistency in clinical outcomes that has plagued obsessive-compulsive disorder stimulation studies for two decades.

Obsessive-compulsive disorder affects roughly one to two percent of the global population, characterized by intrusive, distressing obsessions and repetitive compulsions that can consume hours of each day. For the majority of patients, cognitive behavioral therapy and serotonin reuptake inhibitors provide meaningful relief. But a stubborn minority, estimated at around ten percent, derive little benefit from any conventional treatment. It is this treatment-resistant group for whom deep brain stimulation has been developed, and for whom the stakes of targeting precision are highest. The procedure is invasive, expensive and not without risk, so improving the odds of a successful outcome carries real clinical weight.

The technical approach behind the study relied on diffusion-weighted imaging, which tracks the directional movement of water molecules along axonal bundles to infer the trajectories of white matter tracts. From these data, the researchers constructed individualized connectomes, assigning each stimulation target a connectivity fingerprint describing which brain regions it is structurally linked to and with what strength. By quantifying the overlap and divergence of these fingerprints across patients, the team could measure, for the first time in a systematic way, how much of the apparent uniformity of standard targets is an artifact of averaging, and how much genuine inter-individual variation persists even in a relatively homogeneous patient population.

The results showed that while certain broad network features are conserved, including strong connections between the ventral capsule and striatal targets and prefrontal cortical regions implicated in compulsive behavior, the fine-grained connectivity differs in ways that could be clinically consequential. Some patients exhibited connectivity profiles that aligned closely with the tracts most often associated with favorable stimulation responses in the published literature, such as pathways linking the ventral striatum with medial frontal and limbic regions. Others showed markedly different configurations, with key tracts displaced or attenuated relative to the group average. In such patients, an electrode placed at the conventional coordinate might miss the optimal tract entirely, or engage competing pathways with unknown effects.

These findings dovetail with a growing body of evidence that the therapeutic effect of deep brain stimulation depends less on the precise anatomic address of an electrode and more on the specific white matter tracts it modulates. Parallel work in Parkinson’s disease, dystonia and treatment-resistant depression has converged on the idea that connectivity-informed targeting outperforms anatomy-informed targeting, and that tractographic models derived from patient-specific imaging can predict clinical outcomes better than distance from a group-defined sweet spot. The present study extends this connectomic framework to obsessive-compulsive disorder, providing quantitative evidence that the field’s conventional targets are not network-equivalent across patients.

The clinical implications are straightforward, even if their implementation will take time. The findings argue for incorporating individual diffusion imaging and connectomic analysis into the pre-surgical planning of deep brain stimulation for obsessive-compulsive disorder, rather than relying exclusively on atlas coordinates. They also suggest a framework for rational electrode adjustment, in which a patient’s poor response to stimulation could be reinterpreted as a wiring mismatch rather than a failure of the therapy itself, prompting tractography-guided revision. As imaging pipelines become faster and more automated, the marginal cost of patient-specific connectomic planning continues to fall, bringing such approaches closer to routine practice.

Important caveats remain. The study examined structural connectivity, the brain’s physical wiring, and did not directly measure function or clinical response, so the link between connectomic variability and therapeutic outcome, while strongly suggested, awaits direct validation in longitudinal cohorts. Diffusion imaging itself carries known limitations in resolving crossing fibers and distinguishing fiber populations. Nonetheless, the central message stands with unusual clarity: the brain targets that surgeons stimulate are not interchangeable points on a map, but individualized nodes in each patient’s unique neural network. For a disorder as heterogeneous and disabling as obsessive-compulsive disorder, that individuality may prove to be the key that finally unlocks consistent benefit from one of medicine’s most remarkable interventions.

Subject of Research: Patient-specific structural connectomic variability of deep brain stimulation targets in treatment-resistant obsessive-compulsive disorder

Article Title: Patient-specific structural connectomic differences of deep brain stimulation targets in treatment-resistant obsessive-compulsive disorder patients

Article References: Patient-specific structural connectomic differences of deep brain stimulation targets in treatment-resistant obsessive-compulsive disorder patients. (n.d.). https://doi.org/10.1038/s41398-026-04441-4

Image Credits: AI Generated

DOI: 10.1038/s41398-026-04441-4

Keywords: deep brain stimulation, obsessive-compulsive disorder, connectomics, treatment-resistant OCD, diffusion MRI, white matter tracts, ventral capsule, nucleus accumbens, neurosurgery, translational psychiatry, brain networks, Patient-specific

The subthalamic nucleus, a small lens-shaped structure deep in the brain, sits at a critical junction in the basal ganglia circuitry that governs movement. In Parkinson’s disease, as dopamine-producing neurons in the substantia nigra degenerate, this circuitry falls into disarray. One of the most robust electrophysiological signatures of the disease is an exaggeration of beta-band oscillations, rhythmic fluctuations in the roughly 13 to 30 hertz range, in the subthalamic nucleus. These oscillations have been correlated with the cardinal motor symptoms of Parkinson’s, including bradykinesia, rigidity, and tremor, and their suppression through deep brain stimulation is associated with therapeutic benefit. This has made beta activity a cornerstone biomarker, both for understanding the disease and for engineering next-generation adaptive stimulation devices that deliver therapy only when the pathological signal is detected.

Yet the meaning of the local field potential remains one of the enduring puzzles of systems neuroscience. The LFP is thought to arise primarily from summed synaptic currents flowing across populations of neurons, filtered by the passive electrical properties of the surrounding tissue. Spikes, by contrast, are the discrete action potentials emitted by individual cells, and they contribute comparatively little to the field potential. When researchers observe beta oscillations in the LFP, they infer that the synaptic inputs to subthalamic neurons are oscillating, and they often further assume that the neurons’ output spikes must therefore be modulated in phase with that rhythm. The new findings complicate that second inference. Burst discharges from subthalamic neurons, the study reports, can be found both in phase and in antiphase with the simultaneously recorded beta LFP, and neither relationship dominates in a stable, predictable way.

This inconsistency matters because the phase of a spike relative to an oscillation is not an incidental detail. In the theoretical framework of neural coding, the timing of action potentials relative to population rhythms carries information and shapes downstream communication. Two neurons that receive the same oscillating input but burst on opposite phases of it are, in a functional sense, responding oppositely: one fires when the population signal peaks, the other when it troughs. If the spiking output of the subthalamic nucleus is split between in-phase and antiphase bursting, then a single LFP beta measurement cannot reliably indicate whether the neurons it governs are firing together or in opposition. The aggregate signal may look identical in both situations while the underlying cellular behavior differs fundamentally.

The implications ripple outward into several active areas of research and clinical development. Adaptive deep brain stimulation, one of the most promising advances in the field, uses real-time measurement of beta-band LFP to trigger or modulate stimulation. Devices currently in clinical trials, and early sensing-capable implants already in patients, treat elevated beta power as a proxy for the pathological state of the circuit. If beta power does not map consistently onto the bursting behavior of subthalamic neurons, then the biomarker may sometimes capture a circuit state that differs from the cellular dynamics the stimulation is intended to disrupt. This does not invalidate the approach, since beta suppression demonstrably correlates with symptom relief, but it does suggest that the chain of inference from LFP measurement to neuronal mechanism is weaker than often assumed.

The findings also speak to long-standing debates about the origins of pathological beta oscillations in Parkinson’s disease. Competing models assign different weights to the subthalamic nucleus itself, to its reciprocal connections with the external segment of the globus pallidus, and to cortical input delivered through the hyperdirect pathway. If subthalamic neurons burst in antiphase with the local field oscillation in a substantial fraction of cases, then the relationship between synaptic drive and spiking output in the nucleus is more heterogeneous than many models allow. Inhibitory input from the globus pallidus, which arrives as rhythmic bursts in parkinsonian conditions, could plausibly produce bursts of spikes in subthalamic neurons that occur during phases of suppressed synaptic depolarization in the surrounding population, contributing a sign-inverted component to the spike-LFP relationship. The new results are consistent with such heterogeneity in the sources and signs of rhythmic drive.

Methodologically, the study underscores the importance of examining spike-field relationships at the level of individual units rather than relying on population averages. When spikes from many neurons are pooled, in-phase and antiphase bursting can partially cancel, yielding a weak or ambiguous phase locking statistic that might be dismissed as noise. The more informative observation is that both relationships coexist, often within the same recording session, which means the averaging itself obscures the underlying structure. This echoes a broader lesson in electrophysiology: aggregate signals such as the LFP, electrocorticogram, and scalp EEG are powerful and clinically practical, but their interpretation requires careful attention to the geometry of the sources and the diversity of the cellular responses they summarize.

For patients and clinicians, the immediate practical consequences are limited but worth stating precisely. The therapeutic effectiveness of deep brain stimulation does not depend on the spike-field relationship being in phase; high-frequency stimulation suppresses symptoms regardless, presumably by driving the circuit into a more regular, information-rich regime that disrupts pathological patterning. The concern is prospective: as the field moves toward closed-loop therapies that decode brain state from field potentials, and toward brain-computer interfaces that treat oscillatory phase as a control signal, the assumption that phase reflects cellular firing must be tested rather than assumed. The new results provide a concrete, clinically relevant example where that assumption fails, at least intermittently, in a structure that is the single most common target of functional neurosurgery.

The research also raises questions that future work will need to address. Whether the inconsistent phase relationships reflect differences among neuron types within the subthalamic nucleus, shifts across behavioral states such as rest and movement, fluctuations in the balance of excitatory and inhibitory drive over time, or artifacts of how recording contacts sample spatially extended oscillatory sources remains to be determined. Longitudinal recordings from implanted patients, combined with computational models of the basal ganglia network, offer a path toward resolving which cellular configurations generate which field signatures. Such work could ultimately refine the biomarkers used in adaptive stimulation, allowing devices to distinguish circuit states that currently look identical in the LFP.

In the broader arc of neuroscience, the study is a reminder that the brain’s rhythms are not monolithic expressions of collective firing but composites whose relationship to cellular activity is contingent and, in the parkinsonian subthalamic nucleus, demonstrably inconsistent. The beta oscillation will remain a valuable clinical signal, and the correlation between its power and Parkinsonian symptoms is not in dispute. What the new findings erode is the simpler narrative in which the rhythm and the spikes move as one. In the subthalamic nucleus, neurons can march with the beta wave or against it, and the field potential alone cannot tell an observer which. For a field betting increasingly on oscillations as the language of pathological brain circuits, that ambiguity is a finding worth taking seriously.

Subject of Research: The relationship between subthalamic local field potential beta oscillations and neuronal burst firing in Parkinson's disease.

Article Title: Inconsistent subthalamic local field potential beta activity amid in- and antiphasic neuronal bursts

Article References: Inconsistent subthalamic local field potential beta activity amid in- and antiphasic neuronal bursts. (n.d.). https://doi.org/10.1038/s41531-026-01531-4

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01531-4

Keywords: Parkinson's disease, subthalamic nucleus, local field potentials, beta oscillations, neuronal bursting, deep brain stimulation, basal ganglia, electrophysiology, neural coding, phase-amplitude coupling, brain-computer interfaces, movement disorders

The clinical backdrop is well understood. Levodopa, the gold-standard oral treatment introduced more than half a century ago, delivers dramatic symptom relief early in the disease. But as dopaminergic neurons continue to die, the therapeutic window of each dose narrows. Patients begin cycling unpredictably between “on” states, when medication controls their movement, and “off” states, when symptoms return with disabling force. To compensate, treatment regimens grow into complex schedules of multiple daily doses and adjunct drugs from several classes. Even then, many patients endure five or more hours of daily “off” time, alongside dyskinesia, adherence problems, and side effects. At that point, international guidelines agree that device-aided therapies should be considered: deep brain stimulation, levodopa-carbidopa intestinal gel, continuous subcutaneous apomorphine infusion, and, more recently, subcutaneous foslevodopa-foscarbidopa.

What has been missing until now is rigorous longitudinal evidence about what actually happens to these patients under real-world conditions. Previous data linking poor symptom control to disability, diminished quality of life, and caregiver strain came largely from retrospective analyses, cross-sectional snapshots, or follow-ups too brief to capture disease evolution. PROSPECT, led by Alberto J. Espay of the University of Cincinnati together with an international team, was designed to close that gap. Enrolled patients had a mean age of 67.8 years, roughly equal numbers of men and women, and had lived with Parkinson’s for an average of 8.9 years, with motor fluctuations present for about six years. All had at least 2.5 hours of daily “off” time despite an adequate trial of oral therapy, and none had previously used a device-aided treatment.

The study deliberately imposed no treatment protocol. Clinicians adjusted medications and offered device-aided therapies according to their own judgment, exactly as they would in routine care. Patients kept home diaries for three days before each six-month visit, logging their state every 30 minutes as asleep, off, or on, and noting any dyskinesia. The primary endpoint was the change in daily “off” time from baseline to month 24, normalized to a 16-hour waking day. Secondary measures spanned the MDS-UPDRS Part II for activities of daily living, the Non-Motor Symptoms Scale, sleep quality on the PDSS-2, disease-specific and generic quality of life on the PDQ-39 and EQ-5D-5L, activity impairment, treatment satisfaction, and caregiver strain.

The results split the cohort into two starkly different trajectories. Among the 184 patients, or 80.3 percent, who stayed solely on oral medications, “off” time fell only modestly, from a mean of 5.0 hours per day at baseline to 4.2 hours at month 24, an adjusted reduction of 0.7 hours that the authors characterize as statistically significant but clinically negligible. Meanwhile, scores for activities of daily living worsened, quality of life declined on both the PDQ-39 and EQ-5D-5L, and caregiver strain crept upward. Sleep disturbance also worsened at the 18-month mark. In short, these patients experienced the natural progression of their disease with little meaningful relief, despite regular contact with specialist care and ongoing medication optimization.

The contrasting group told a different story. Roughly half of all participants, 49.8 percent, were offered a device-aided therapy at some point during the study, most commonly neurosurgical options such as deep brain stimulation, followed by levodopa-carbidopa intestinal gel and subcutaneous apomorphine infusion. Of the 114 patients offered such a therapy, 44.7 percent declined. The most frequent reasons were needing more time to decide, cited by 54.9 percent of decliners, feeling the therapy was not yet necessary, at 45.1 percent, and safety concerns about the procedure, at 25.5 percent. Ultimately only 45 patients, 19.7 percent of the cohort, initiated a device-aided therapy during the two years.

Those who made the switch saw benefits that dwarfed anything achievable with pills alone. Their “off” time dropped from a mean of 4.8 hours per day at baseline to 2.6 hours at month 24, an adjusted reduction of 2.2 hours daily that was sustained from month 6 onward. This was accompanied by a significant 2.4-hour increase in “on” time without any dyskinesia, and both improvements were significantly greater than in the oral-medication group. Patients who initiated device-aided therapy also avoided the gradual worsening in daily functioning seen in their pill-only counterparts, and their levodopa-equivalent daily doses fell dramatically, from a mean of 1,149 milligrams at baseline to 553 milligrams at month 24, compared with essentially unchanged oral dosing in the other group. Sleep quality improved transiently, and treatment satisfaction rose at 18 months, although several quality-of-life measures in this smaller subgroup remained statistically unchanged.

The adoption gap exposes barriers on both sides of the consultation room. More than 40 percent of eligible patients were never even offered a device-aided option, a decision that rested entirely on physician judgment in the absence of standardized selection criteria or clear timing guidance. The authors point to prior evidence that clinicians’ recommendations vary with personal experience, perceived logistical hurdles, geographic availability, and the lack of head-to-head comparative data among modalities. Local access mattered too: continuous subcutaneous apomorphine infusion was commercially available in only four of the seven participating countries during the study, and a survey of Japanese neurologists showing a preference for non-surgical options may explain the disproportionately low uptake among Japanese patients. On the patient side, hesitancy, indecision, and the perception that invasive procedures can wait reflect a broader problem of inadequate shared decision-making, with studies showing patients often feel uninformed about their advanced-therapy options.

There are important caveats. The cohort was recruited from experienced movement disorder and general neurology clinics, so outcomes may differ for patients without access to expert care. Patient-reported diaries are vulnerable to recall bias and Hawthorne effects, in which awareness of being monitored alters behavior and perception. The device-aided subgroup was small, and patients could initiate therapy at any point, limiting statistical power and complicating comparisons among modalities. The authors also note that the study population appeared somewhat less severely affected at baseline than cohorts in previous device-therapy trials, likely because PROSPECT captured routine practice rather than trial-selected patients, and because the most symptomatic patients may have already initiated device therapy before enrollment. The 24-month window, while long for observational work in this space, may still have been too short to capture the full toll of progressive disease.

Even with those limitations, the message is difficult to ignore. Patients who remained on oral medications alone stayed largely uncontrolled for two years while their disability and quality of life slowly eroded, whereas those who accepted device-aided therapy achieved sustained, clinically meaningful reductions in “off” time consistent with the established efficacy of these treatments. The authors argue that earlier, proactive conversations among clinicians, patients, and caregivers, supported by structured decision aids and tools such as MANAGE-PD for identifying candidates, could help close the gap between eligibility and treatment. Whether earlier intervention ultimately translates into better long-term outcomes will require dedicated comparative studies with extended follow-up. For now, PROSPECT provides the clearest real-world picture yet of what happens when effective advanced therapies sit on the shelf: the disease simply keeps moving, and the patients move with it.

Subject of Research: Real-world treatment patterns and 24-month outcomes of Parkinson's disease patients with uncontrolled motor fluctuations, comparing continued oral medication with initiation of device-aided therapy in the PROSPECT observational study.

Article Title: Impact of Uncontrolled Motor Fluctuations in Parkinson’s Disease: Real-World Insights from the PROSPECT Observational Study

Article References: Espay, A. J., Defebvre, L., de Fabregues, O., Falconer, D., Hasegawa, K., Houghton, D., Ledingham, D., Lehn, A., Mestre, T. A., Oeda, T., Ory-Magne, F., Sarna, J. R., Safarpour, D., Colman, S., Bergmann, L., Kukreja, P., Onuk, K., Yan, C. H., & Alonso, P. S. (2026). Impact of Uncontrolled Motor Fluctuations in Parkinson’s Disease: Real-World Insights from the PROSPECT Observational Study. Advances in Therapy. https://doi.org/10.1007/s12325-026-03793-z

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03793-z

Keywords: Parkinson's disease, motor fluctuations, device-aided therapy, deep brain stimulation, levodopa-carbidopa intestinal gel, off time, quality of life, PROSPECT study, observational study, advanced Parkinson's disease, levodopa, real-world evidence

The authors call the first approach restorative normalization, or RN. It is the philosophy underlying most rehabilitation efforts after stroke, psychiatric illness or neurodegeneration: if neural activity has drifted from a healthy pattern, stimulation should nudge it back. The second approach they name compensatory amplification, or CA. Rather than normalizing activity, CA deliberately enhances repurposed brain processes—alternative networks, rhythms or strategies that the nervous system spontaneously deploys when its usual routes are compromised. The distinction may sound subtle, but the researchers argue it has profound consequences for how stimulation targets are chosen, how patients are selected for trials, and how success is defined.

The framework rests on four pillars drawn from cognitive neurophysiology. The first is multiple realizability: the idea, long established in cognitive science, that the same behavior or cognitive function can be supported by more than one neural configuration. Degeneracy and redundancy in brain networks mean that a lesion to one circuit does not necessarily abolish the function it served, because parallel circuits can take over. The second pillar is multiscale neuroplasticity. The brain adapts at many levels simultaneously—from molecular and synaptic changes to large-scale network reorganization—and these nested layers of plasticity provide the raw material that compensatory amplification can exploit.

The third enabling factor is precision readiness. Modern neuromodulation now possesses an unusually rich toolkit: transcranial direct, alternating and random noise stimulation, rhythmic transcranial magnetic stimulation, focused ultrasound, and invasive deep brain stimulation, increasingly guided by individualized connectome maps and closed-loop control. Electric field modeling, lesion network mapping and personalized targeting have matured to the point where clinicians can, in principle, deliver stimulation with circuit-level specificity. The fourth pillar is activity selectivity: the recognition that stimulation interacts with the brain’s ongoing state, and that the same protocol can have opposite effects depending on which neural populations are active when the current arrives. Together, these four factors make it feasible not merely to perturb the brain, but to selectively strengthen the compensatory processes that matter.

Stroke rehabilitation offers the clearest clinical arena in which the two strategies interplay. Traditional restorative approaches have often sought to dampen the unaffected, contralesional hemisphere, on the theory that it exerts excessive inhibition over the damaged side. But a substantial body of imaging work shows that many well-recovered patients rely heavily on exactly those contralesional motor areas and ipsilateral pathways. For such patients, suppressing the workaround would be counterproductive; amplifying it could be the better treatment. The authors argue that patient stratification—identifying who depends on compensatory circuits and who retains the capacity for true restoration—should become a central design principle in stimulation trials rather than an afterthought.

The framework’s reach extends well beyond stroke. In neurodegenerative disease, compensatory signatures appear remarkably early. Studies have documented prefrontal recruitment in older adults carrying amyloid-beta pathology, altered hemispheric asymmetry in mild cognitive impairment, and cortical compensation in cognitively unimpaired Parkinson’s disease patients. Indeed, one recent analysis found that clinical severity in Parkinson’s disease tracks the decline of cortical compensation itself. If those compensatory mechanisms can be detected—and the authors point to high-density electrical stimulation protocols that restored working memory and long-term memory function in older adults by resynchronizing rhythmic brain circuits—then amplification strategies might delay decline or expand residual processing capacity even as underlying pathology progresses.

Psychiatry presents a different but equally compelling case. Compensatory network activity has been documented in schizophrenia, major depression, obsessive-compulsive disorder, anxiety and attention deficit hyperactivity disorder, sometimes marking resilience and sometimes maladaptation. Deep brain stimulation studies in depression and obsessive-compulsive disorder have revealed that therapeutic effects correlate with measurable changes in frontostriatal and cingulate dynamics, and that stimulation responses depend on the patient’s moment-to-moment brain state. A compensatory amplification lens suggests that some of these interventions may succeed not by normalizing pathological activity but by reinforcing adaptive workarounds—and that distinguishing adaptive from maladaptive compensation could sharpen target selection in precision psychiatry.

Healthy aging, too, falls within scope. Classic findings such as the HAROLD model of reduced hemispheric asymmetry and the posterior-to-anterior shift in aging neural recruitment describe how older brains reorganize to preserve performance. A 2023 meta-analysis by the same group concluded that transcranial alternating current stimulation improves cognition across healthy, aging and psychiatric populations. Framing such gains as compensatory amplification rather than restoration, the authors contend, yields testable predictions: stimulation should be most effective when it is timed and tuned to amplify signatures of successful compensation, and those signatures—oscillatory synchrony patterns, network recruitment profiles, behavioral strategy shifts—can be measured before treatment ever begins.

The perspective is deliberately conceptual rather than empirical; it reports no new data. But its authors argue that positioning compensatory amplification alongside restorative normalization as a core design principle can do three concrete things: sharpen target selection by asking which neural process a protocol is meant to strengthen, guide stratified treatments by matching patients to the strategy their brains can actually use, and translate the vast literature on compensatory signatures into specific, falsifiable stimulation protocols. In an era when neuromodulation is moving from crude blunt instruments toward circuit-precise, state-aware interventions, the question is no longer only how to repair the brain, but when to amplify what the brain is already trying to do for itself.

Subject of Research: Neuromodulation strategies for restoring and amplifying brain function through restorative normalization and compensatory amplification

Article Title: Neuromodulation for restoring and amplifying brain function

Article References: Grover, S., Wen, W., & Reinhart, R. M. G. (2026). Neuromodulation for restoring and amplifying brain function. Nature Neuroscience. https://doi.org/10.1038/s41593-026-02434-6

Image Credits: AI Generated

DOI: 10.1038/s41593-026-02434-6

Keywords: neuromodulation, brain stimulation, compensatory amplification, restorative normalization, neuroplasticity, stroke rehabilitation, neurodegeneration, psychiatry, cognitive aging, deep brain stimulation, tACS, working memory

The commentary, authored by Anneke van der Weide, Y. Wiggerts, D. Hubers and colleagues, responds to work in the growing field of data-driven contact selection. In deep brain stimulation of the subthalamic nucleus, the surgical target most commonly used for Parkinson’s disease, a quadripolar or directional lead is implanted with multiple metal contacts along its shaft. Postoperatively, the clinical team must choose which contact or combination of contacts to activate, a decision traditionally made through painstaking trial and error during programming sessions, guided by the patient’s symptom response and the emergence of side effects such as contralateral motor symptoms, speech difficulties, dysarthria, autonomic changes or mood shifts.

For decades this selection process has been as much art as science. The volume of tissue activated, the spatial relationship between each contact and the patient’s individually delineated motor subregion of the subthalamic nucleus, and the distance from fiber tracts such as the hyperdirect and corticospinal pathways all influence the therapeutic window. Modern approaches therefore combine structural and diffusion-weighted magnetic resonance imaging, sometimes with intraoperative or postoperative computed tomography to localize the lead, to generate patient-specific models of electric field spread. Machine learning classifiers trained on retrospective programming outcomes have been proposed to rank contacts by their probability of producing benefit with minimal adverse effects, and several groups have reported accuracies that appear to approach or exceed inter-rater agreement among expert programmers.

The authors of the commentary do not dispute the promise of these methods. Rather, they argue that the reported performance of predictive models can obscure fundamental obstacles to clinical translation. One central concern is the definition of the ground truth itself. When an algorithm is trained on the contact that a programmer ultimately chose, or on the contact associated with the best clinical outcome at follow-up, the labels inherit all the inconsistencies of real-world practice. Programming decisions vary across centers, across devices and across the experience levels of the clinicians involved. Follow-up intervals differ, medication states confound motor assessments, and the contact that is optimal at three months may not be optimal at one year as the disease evolves, as tissue reaction around the lead matures and as stimulation parameters are adjusted.

A second concern involves the validation standard that new algorithms are held to. Comparing a model’s prediction against a single human expert’s choice can make the model look artificially good or artificially bad depending on that expert’s idiosyncrasies. Comparing against consensus ratings from multiple blinded experts is more rigorous but raises its own question: if experts themselves disagree, what exactly is the model being trained to reproduce? The commentary emphasizes that metrics such as accuracy, area under the receiver operating characteristic curve or F1 score, while useful for benchmarking, do not by themselves establish that a model will change clinical decisions or improve patient outcomes. What matters, the authors contend, is prospective demonstration that algorithm-assisted selection shortens the time to stable therapy, reduces the number of programming visits, or measurably improves motor and quality-of-life outcomes compared with standard care.

The commentary also addresses the practical heterogeneity of the implanted hardware, a problem that is easy to underestimate. Different manufacturers offer leads with different contact geometries, contact spacings, degrees of directional segmentation and current-shaping capabilities, and the field is moving toward adaptive and closed-loop devices that sense local field potentials and adjust delivery in real time. A predictive model trained exclusively on ring-mode contacts from one device generation may not transfer cleanly to segmented directional leads from another, where the effective anatomical coverage of a contact changes with rotation and with the use of multiple simultaneous current fractions. Imaging pipelines add further variability: direct lead localization from postoperative CT, registration errors between CT and preoperative MRI, and the choice of atlas or patient-specific segmentation of the subthalamic nucleus can each shift the computed relationship between a contact and the motor territory by a fraction of a millimeter to a millimeter or more, which is on the order of the distances that differentiate a good contact from a poor one.

Data quantity and quality present a related bottleneck. High-quality labeled datasets are scarce because they require patients who have undergone detailed imaging, careful postoperative programming and structured long-term follow-up. Multicenter pooling is the obvious solution, but pooling introduces harmonization problems across scanner platforms, surgical techniques and outcome measures. The commentary suggests that the field needs agreed reporting standards, shared benchmarks and ideally openly available datasets with common definitions of what constitutes a successful contact selection, so that competing algorithms can be compared on equal footing rather than on private, incomparable cohorts.

Perhaps the most clinically resonant part of the argument concerns workflow integration. Even a well-validated model provides only a ranked list of candidate contacts with associated confidence levels. The clinician in the programming room must reconcile that ranking with information the model may not see: the patient’s reported sensations during test stimulation, medication timing, cognitive and psychiatric history, the patient’s priorities between mobility and speech, and the practical constraints of the device’s battery and safety limits. The authors argue that tools framed as decision support rather than decision replacement are far more likely to be adopted. If the algorithm presents its top candidates together with the anatomical reasoning, for example the estimated overlap with the motor territory and proximity to internal capsule fibers, the clinician can interrogate the recommendation, override it when the clinical picture demands it, and learn from the interaction. A black-box ranking delivered without explanation invites either blind trust or justified skepticism, and neither serves the patient.

The commentary also raises the question of when in the therapeutic trajectory such tools should be applied. Early programming, in the first weeks after lead implantation, is arguably where prediction offers the greatest payoff, because the therapeutic window is often narrow and empirical exploration is slowest and most burdensome for the patient. But it is also when the perioperative state, including microlesion effects from electrode insertion and residual swelling, can distort the relationship between anatomy and stimulation response. Later, after months of chronic stimulation, the picture stabilizes but many patients have already reached a satisfactory configuration, reducing the marginal value of prediction. Striking the right moment for algorithmic input, and designing studies that measure outcomes at that moment, is part of the bridging work the authors call for.

Equity and generalizability form another layer of the argument. If training cohorts are drawn disproportionately from high-volume academic centers in a small number of countries, the resulting models may encode narrow surgical and programming cultures. Contact selection reflects local conventions, such as preferred current settings, typical amplitudes and the aggressiveness of medication reduction, all of which differ internationally. A model that silently learns those conventions will perform differently when deployed elsewhere. The commentary implies that algorithm developers should document the provenance of their training data as carefully as they document their model architecture, and that prospective multi-center trials are the only way to establish that performance generalizes beyond the development environment.

None of these criticisms amount to a rejection of computational contact selection. On the contrary, the commentary’s tone is constructive: the field has generated genuinely exciting predictive tools, and the authors’ argument is that the next phase of progress depends on methodological discipline rather than additional architectural novelty. They call for standardized outcome definitions, blinded expert consensus labels, external validation on fully independent cohorts, transparent reporting of failure cases, and ultimately randomized prospective studies in which algorithm-guided programming is compared with conventional care on patient-centered endpoints such as time to therapeutic benefit, number of programming sessions and quality-of-life measures.

For patients, the stakes are concrete. Every programming visit represents time away from work and family, and every suboptimal contact configuration can mean months of avoidable tremor, rigidity, slowness or stimulation-induced side effects. An algorithm that reliably narrowed the search from four or more candidate contacts to one or two could meaningfully compress the journey to stable therapy. The commentary’s authors make clear that they believe this goal is achievable, but only if developers and clinicians build the bridge together, with algorithms designed around the realities of the programming room rather than the metrics of the machine learning benchmark.

As deep brain stimulation expands beyond Parkinson’s disease into dystonia, essential tremor, epilepsy, obsessive-compulsive disorder and treatment-resistant depression, and as sensing-enabled adaptive devices become standard, the number of degrees of freedom in stimulation delivery will only grow. Manual exploration of that expanded parameter space will become progressively less feasible, which makes trustworthy predictive tools not a luxury but a necessity. The contribution of this Matters Arising piece is to define, with clinical precision, what “trustworthy” will have to mean: models validated against consensus truth, tested prospectively, explained transparently and integrated respectfully into the judgment of the clinicians who remain accountable for the person attached to the lead.

Levodopa remains the most effective medication for controlling many of the movement symptoms associated with Parkinson’s disease. After entering the brain, it is converted into dopamine, the chemical messenger that becomes deficient as dopamine-producing neurons degenerate. The medication can improve slowness, rigidity and, in some patients, tremor, but its effects are not always stable. As the disease progresses, the therapeutic window may narrow, meaning that the dose needed to improve movement can approach the dose that causes involuntary movements known as dyskinesias. This fluctuation makes treatment highly individual and creates a need for biological measurements that reveal how the brain responds, rather than relying only on outward symptoms.

Deep brain stimulation, or DBS, offers a unique opportunity to search for those measurements. In DBS, surgeons implant electrodes into carefully selected structures deep within the brain, most commonly the subthalamic nucleus for Parkinson’s disease. A pulse generator then delivers patterned electrical stimulation intended to normalize abnormal neural signaling. The therapy can reduce motor symptoms and lessen dependence on medication, but programming it remains a complex process. Clinicians must choose stimulation contacts, electrical amplitude, pulse width and frequency, often through repeated adjustments over weeks or months. Physiological biomarkers—measurable signals linked to brain or body function—could make this process more precise by showing when stimulation is engaging the intended circuits and how levodopa changes the same signals.

The term “physiomarker” encompasses a broad range of measurable biological features. In Parkinson’s research, these may include neural oscillations recorded from implanted electrodes, muscle activity measured with electromyography, motion captured by wearable sensors, or patterns in a patient’s walking, tremor and muscle tone. One widely studied signal is beta-band activity, a rhythm in the approximate 13-to-30-hertz range that is often associated with motor control and becomes unusually prominent in Parkinson’s disease. Dopamine replacement and DBS can both influence abnormal beta activity, although the relationship is not simple or identical in every patient. By examining levodopa-related changes during stimulation, researchers hope to identify signals that reflect therapeutic benefit, medication state or the risk of unwanted movements.

The importance of studying the two treatments together lies in their overlapping but distinct mechanisms. Levodopa changes the chemical environment of motor circuits by restoring dopamine-related signaling, while DBS changes the electrical dynamics of those circuits through externally delivered pulses. A biomarker that responds to levodopa may not respond in the same way to stimulation, and a signal that reflects improvement under medication may behave differently when DBS is active. Separating these effects could help clinicians determine whether a symptom is best addressed by adjusting a drug dose, changing stimulation settings or combining both approaches. It could also clarify why patients with apparently similar symptoms can require very different treatment strategies.

The study’s focus is particularly relevant to the development of adaptive DBS, sometimes called closed-loop stimulation. Conventional DBS delivers stimulation according to fixed settings, even though a patient’s symptoms and brain state can vary across the day with medication cycles, fatigue, stress, sleep and movement demands. Adaptive systems aim to detect a physiological signal and automatically adjust stimulation in response. For such systems to work safely, researchers must know which biomarkers are reliable, how quickly they change, and whether they represent improvement, medication fluctuations or the emergence of dyskinesia. Levodopa-related physiomarkers could become part of the biological language that future stimulators use to tailor therapy moment by moment.

The research also speaks to a broader shift in neurology: treatment is increasingly being evaluated through objective, continuously collected data. A patient’s report remains essential, but a clinic visit offers only a brief snapshot of a condition that may change substantially throughout the day. Wearable sensors and implanted recording technologies can capture movement and neural activity over longer periods, potentially revealing patterns that are invisible during a conventional examination. If a physiological signal can be consistently linked to levodopa response during DBS, it may eventually support more individualized dosing, improve the interpretation of stimulation effects and reduce the trial-and-error process that currently accompanies advanced Parkinson’s care.

However, biomarkers are not automatically ready for clinical use simply because they are measurable. A useful marker must be reproducible across patients, stable enough to guide decisions and closely connected to outcomes that matter, such as walking, hand function, speech, balance or involuntary movement. Parkinson’s disease is biologically diverse, and the same neural rhythm may carry different information in different people or brain regions. Medication timing also matters: levodopa absorption, metabolism and delayed effects can alter the signals being recorded. Stimulation itself may interfere with sensing, creating technical challenges for devices that must deliver electrical pulses while simultaneously detecting subtle neural activity. These limitations make careful validation essential before a physiomarker can control therapy automatically.

By placing levodopa-related signals at the center of DBS research, de Neeling, Oehrn, Stam and their colleagues contribute to a field seeking a more detailed map of Parkinson’s treatment response. The significance of the work lies not only in any single biomarker, but in the possibility of connecting medication, electrical stimulation and measurable physiology within one framework. Such an approach could help transform DBS from a largely manually programmed therapy into a responsive treatment that adapts to the patient’s changing state. The findings will need to be interpreted alongside larger clinical studies and long-term testing, but the direction is clear: the future of Parkinson’s care may depend on listening to the brain’s signals as carefully as clinicians observe the patient’s movements.

Subject of Research: Levodopa-related physiological biomarkers during deep brain stimulation in Parkinson’s disease

Article Title: Levodopa-related physiomarkers during deep brain stimulation in Parkinson’s disease

Article References: de Neeling, M.G.J., Oehrn, C.R., Stam, M.J. et al. “Levodopa-related physiomarkers during deep brain stimulation in Parkinson’s disease.” npj Parkinson’s Disease (2026). https://doi.org/10.1038/s41531-026-01521-6

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01521-6

Keywords: Parkinson’s disease, levodopa, deep brain stimulation, physiomarkers, biomarkers, adaptive DBS, dopamine, neuromodulation

The study centers on motor-thalamus DBS, a strategy explored for movement disorders and related symptoms. Instead of treating stimulation as a single fixed setting, the researchers tested multiple frequencies and monitored changes in speech-related signals and swallowing performance. This frequency sensitivity points to circuit-level dynamics where different stimulation rates engage distinct neural processing modes.

In practical terms, the results imply that higher or lower frequencies may preferentially drive or suppress specific pathways that contribute to oral motor timing. Speech production relies on precisely coordinated patterns of muscle activation, airflow, and sensory feedback; swallowing requires rapid, sequence-based control to protect the airway. Alterations in these timing networks could explain why DBS can influence both functions simultaneously.

The authors describe the effects as frequency-dependent, meaning that the same DBS target produces divergent outcomes when the pulse rate changes. Such divergence is consistent with the idea that stimulation can shift synaptic interactions, firing synchrony, and network oscillations within the thalamocortical loop. When the stimulation rhythm matches intrinsic circuit oscillations, the brain may stabilize certain motor programs; at other rates, it may destabilize them.

Importantly, the work frames DBS not only as a way to modulate symptoms, but as a potential tool for “behavioral steering.” If translated to clinical settings, clinicians could adjust DBS frequency to reduce speech side effects while maintaining or improving swallowing safety, rather than relying on a one-size-fits-all configuration.

The study also highlights an often-overlooked challenge: therapies optimized for movement may inadvertently affect speech and swallowing, both of which share overlapping motor control resources. Frequency tuning could become a lever for mitigating such trade-offs, improving quality of life for patients who already depend on DBS.

While the research is mechanistic, its implications are immediately viral-science-worthy: the possibility that a single hardware intervention can be dynamically optimized for nuanced functions. The next step will be confirming how these frequency effects scale across different individuals and disease states.

As DBS devices become more programmable, the field is moving toward personalized stimulation “dial settings.” This report adds to that momentum by providing evidence that the motor thalamus does not respond uniformly—frequency matters, and the brain appears to treat different pulse rates as different control regimes.

Subject of Research: Deep brain stimulation (DBS) targeted to the motor thalamus and its frequency-dependent effects on speech and swallowing.

Article Title: Frequency-dependent effects of motor thalamus deep brain stimulation on speech and swallowing.

Article References: Tang, L.W., Grigsby, E.M., Damiani, A. et al. Frequency-dependent effects of motor thalamus deep brain stimulation on speech and swallowing. Nat Commun (2026). https://doi.org/10.1038/s41467-026-75588-3

Image Credits: AI Generated

DOI: 10.1038/s41467-026-75588-3

Keywords:

Axial symptoms—manifesting as balance difficulties, gait disturbances, and postural instability—represent some of the most debilitating and treatment-resistant features of Parkinson’s disease. While STN-DBS involves implanting electrodes in the brain to modulate abnormal subthalamic nucleus activity, LCIG delivers a continuous dopaminergic infusion directly into the small intestine to smooth out motor fluctuations. Until now, the nuanced long-term impact of these treatments on axial functions remained unclear.

The study employed rigorous longitudinal assessments of patients undergoing either STN-DBS or LCIG therapy. Using standardized clinical scales and objective gait analysis over extended follow-up periods, the researchers documented divergent trajectories in axial symptom progression. They report that STN-DBS patients initially experience notable improvement in axial motor control; however, over time, these benefits wane and axial symptoms may even worsen. Conversely, LCIG recipients show more stable axial function, with fewer declines observed years after treatment initiation.

These findings carry immense clinical implications. Understanding the differential effects on axial symptoms can inform tailored therapeutic decision-making, particularly for patients at high risk of falls and mobility loss. The study also highlights the underlying neurophysiological mechanisms distinguishing these treatments: STN-DBS primarily targets aberrant basal ganglia circuitry via electrical modulation, whereas LCIG restores dopaminergic tone continuously, influencing widespread motor pathways.

Moreover, the research underscores the importance of comprehensive monitoring protocols that specifically evaluate axial motor domains. As Parkinson’s disease progresses, axial impairment often dictates quality of life and independence far more than limb motor symptoms. This study champions a shift from merely controlling tremor and rigidity to preserving core postural functions in the long term.

While the benefits of STN-DBS on overall motor fluctuations remain undeniable, the revelation of its potentially limited efficacy on axial symptoms over time calls for adjunctive strategies or alternative interventions. LCIG’s relative stability in this realm suggests that continuous dopaminergic delivery may confer protective effects against axial deterioration.

Future investigations are warranted to decode the neurobiological substrates driving these differential outcomes, possibly guiding innovative therapies combining electrical and pharmacological approaches. This research lays the groundwork for a more nuanced understanding of Parkinson’s motor complications and how to mitigate them strategically.

In the quest to improve the lives of millions afflicted by Parkinson’s disease worldwide, these insights represent a critical stride toward personalized, symptom-specific treatment paradigms. As our knowledge deepens, so does hope for maintaining mobility and autonomy in this challenging neurodegenerative disorder.

Subject of Research: Long-term effects of STN-DBS and LCIG therapies on axial symptoms in Parkinson’s disease.

Article Title: STN-DBS and LCIG differentially affect long-term axial symptoms in Parkinson’s disease.

Article References:
Colucci, F., Kaymak, A., Antenucci, P. et al. STN-DBS and LCIG differentially affect long-term axial symptoms in Parkinson’s disease. npj Parkinsons Dis. (2026). https://doi.org/10.1038/s41531-026-01453-1

Image Credits: AI Generated